You are here: Industry Insights > Galapagos

News List

Gilead Inks 10-year $5B Deal with Galapagos contractpharma
July 16, 2019
Gains access to Galapagos’ discovery platform and current and future pipeline outside of Europe.
Gilead Sciences, Galapagos enter into deal worth $5B biospectrumasia
July 15, 2019
Galapagos will receive a $3.95 billion upfront payment and a $1.1 billion equity investment from Gilead.
Galapagos and Gilead announce positive Phase III results for filgotinib pharmaceutical-technology
April 23, 2019
Galapagos and Gilead announce positive Phase III results for filgotinib.
Evotec and Galapagos collaborate for new fibrosis target pharmaceutical-technology
February 20, 2019
German biotechnology company Evotec has entered into a collaboration agreement with Belgo-Dutch pharmaceutical firm Galapagos for a new, undisclosed target to treat fibrosis....
AbbVie assumes full development and commercial control of CF programme pharmatimes
October 25, 2018
AbbVie has announced that it will assume full development and commercial responsibility for its collaboration with Galapagos to discover and develop new therapies to treat cystic fibrosis (CF).
Novartis Enters into License Agreement with Galapagos, MorphoSys americanpharmaceuticalreview
July 24, 2018
Novartis has entered into an exclusive license agreement with biotech companies Galapagos NV, Mechelen and MorphoSys regarding their compound MOR106.
Novartis pays €95M to bag dermatitis drug from Galapagos, MorphoSys fiercebiotech
July 23, 2018
Novartis is set to pay €95 million ($110 million) upfront for the global rights to Galapagos and MorphoSys’ anti-IL-17C antibody MOR106.
Novartis pays €95M to bag dermatitis drug from Galapagos, MorphoSys fiercebiotech
July 20, 2018
Novartis is set to pay €95 million ($110 million) upfront for the global rights to Galapagos and MorphoSys’ anti-IL-17C antibody MOR106. The deal positions Novartis to take MOR106 forward in atopic dermatitis and other indications, handing over up to €850
AbbVie dumps Galapagos’ cystic fibrosis combo on back of underwhelming data drop fiercebiotech
July 09, 2018
AbbVie has dumped one of Galapagos’ cystic fibrosis regimens after getting a look at underwhelming clinical data on a component of the triple combination.
Galapagos to take IPF drug into late-stage trial after phase 2 win fiercebiotech
August 11, 2017
Some patients showed an increase in lung function over the course of only 12 weeks of treatment.

Previous page 1 2 3 Next page